PPARG and endometrial cancer: Hong et al. examined the effects of the PPARγ agonists 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes, and its p-t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-pPhC6H5) substituents, in endometrial cancer and revealed that the PPARγ-active C-DIMs not only diminished the proliferation of HEC1A endometrial cancer cells, but also promoted the induction of apoptotic cancer cell death by reducing the mitochondrial membrane potential and inducing the release of cytochrome c, the activation of caspases, as well as the nuclear uptake of endonuclease G [44].